23.10.2018

MagForce AG Publishes Financial Results for the First Half of 2018 and Operative Highlights

Berlin, Germany and Nevada, USA, October 24, 2018 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results for the first half of 2018, ending on June 30, 2018, and ...

 

18.10.2018

MagForce AG to host Lunch Symposium on Local Therapies for Malignant Gliomas at the 18th European Congress of Neurosurgery (EANS2018)

Berlin, Germany and Nevada, USA, October 18, 2018 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, is pleased to announce that it will host a scientific lunch symposium titled "Local Therapies ...

 

03.09.2018

MagForce AG to participate in nine upcoming international conferences in H2 2018

Berlin, Germany and Nevada, USA, September 3, 2018 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in nine upcoming scientific and investor conferences in the ...

 

09.08.2018

MagForce AG announces positive results of 2018 Annual General Meeting

Berlin, Germany, and Nevada, USA, August 9, 2018 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, held its Annual General Meeting in Berlin today. The Annual General Meeting approved all resolution ...

 

08.08.2018

MagForce AG announces successful capital increase of the subsidiary MagForce USA, Inc.

Berlin, Germany, and Nevada, USA, August 8, 2018 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced the successful completion of a capital increase of its subsidiary MagForce USA, ...